Drug intelligence / Profile preview

peiminine

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral, Intraperitoneal, Intravenous, Intranasal
01

Overview

Peiminine is a steroidal alkaloid primarily isolated from the bulbs of various Fritillaria species, such as Fritillaria thunbergii and Fritillaria ussuriensis. It is a principal bioactive component in traditional Chinese medicine, where it is used for its expectorant and antitussive (cough suppressant) properties[1][4][5][10]. Peiminine displays a range of pharmacological effects, including strong anti-inflammatory, analgesic, and antitumor activities[4][10]. Mechanistically, it increases cyclic AMP (cAMP) and inhibits M2 muscarinic acetylcholine receptors (mAChRs); it may additionally modulate transient receptor potential channels TRPV1 and TRPA1[1]. In vitro and in vivo studies have demonstrated that peiminine suppresses signaling pathways such as PI3K–Akt, ERK1/2, MAPK, and NF-κB, resulting in the inhibition of cancer cell proliferation, induction of autophagy- and apoptosis-mediated cell death, and attenuation of inflammatory responses[1][3][4][6][9][10]. Preclinical research indicates peiminine's therapeutic potential against diseases like pulmonary fibrosis, osteoarthritis, glioblastoma, lung cancer, and osteosarcoma, but it is not approved as a pharmaceutical drug in any jurisdiction[4][6][9][10].

Other names
verticinone
02

Targets

PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)AKT2 (Rac-beta serine/threonine-protein kinase)MEK2 (Dual specificity mitogen-activated protein kinase kinase 2)SRC (Proto-oncogene tyrosine-protein kinase Src)TRPA1 (Transient receptor potential cation channel subfamily A member 1)FASLG (Fas ligand)MAPK3 (Mitogen-activated protein kinase 1)CHRM2 (M2)NF-κBTRPV1 (Transient receptor potential cation channel subfamily V member 1)PRKCA (Protein kinase C alpha)JAK3 (Janus kinase 3)

Beyond the preview

Go deeper on peiminine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on peiminine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call